Literature DB >> 3777172

Role of glucagon in splanchnic hyperemia of chronic portal hypertension.

J N Benoit, B Zimmerman, A J Premen, V L Go, D N Granger.   

Abstract

The role of glucagon as a blood-borne mediator of the hyperdynamic circulation associated with chronic portal venous hypertension was assessed in the rat portal vein stenosis model. Selective removal of pancreatic glucagon from the circulation was achieved by intravenous infusion of a highly specific glucagon antiserum. Blood flow to splanchnic organs, kidneys, and testicles was measured with radioactive microspheres, and the reference-sample method. Glucagon antiserum had no effect on blood flow in the gastrointestinal tract of sham-operated (control) rats. However, the antiserum produced a significant reduction in hepatic arterial blood flow in the control rats, suggesting that glucagon contributes significantly to the basal tone of hepatic arterioles. In portal hypertensive rats glucagon antiserum significantly reduced blood flow to the stomach (22%), duodenum (25%), jejunum (24%), ileum (26%), cecum (27%), and colon (26%). Portal venous blood flow was reduced by approximately 30%. The results of this study support the hypothesis that glucagon mediates a portion of the splanchnic hyperemia associated with chronic portal hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3777172     DOI: 10.1152/ajpgi.1986.251.5.G674

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  21 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  Portal hypertension--25 years of progress.

Authors:  B R MacDougall; D Westaby; L A Blendis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Evaluation of portal-systemic shunting in rats from mesenteric and splenic beds.

Authors:  R E Stauber; F W Ruthardt; W N Tauxe; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

4.  Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension.

Authors:  M P Pizcueta; J M Piqué; J Bosch; B J Whittle; S Moncada
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

5.  Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.

Authors:  A I Sarela; F M Mihaimeed; J J Batten; B R Davidson; R T Mathie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

6.  Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.

Authors:  M Huonker; Y O Schumacher; A Ochs; S Sorichter; J Keul; M Rössle
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

7.  Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats.

Authors:  L Moreno; M A Martínez-Cuesta; J M Piqué; J Bosch; J V Esplugues
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

8.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Gastric emptying of liquids and solids in the portal hypertensive rat.

Authors:  J A Reilly; C F Forst; E M Quigley; L F Rikkers
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

10.  Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits.

Authors:  P A Cahill; Y Wu; J V Sitzmann
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.